Introduction: The direct thrombin inhibitor dabigatran interferes with thrombophilia screening and with the diagnosis of hemostasis disorders that develop during treatment with the anticoagulant. In vitro addition of idarucizumab, a humanized antibody fragment that binds dabigatran, to plasma samples containing dabigatran fully neutralizes the drug. This study was carried out to determine whether binding of dabigatran on selected insoluble commercial adsorbent material, DOAC-STOP R , was as efficient as idarucizumab to neutralize the anticoagulant activity of the drug in vitro.
| INTRODUC TI ON
Dabigatran is a direct oral anticoagulant inhibiting thrombin, which is administered as a prodrug, dabigatran etexilate. 1 Dabigatran dose-dependently prolongs coagulation assays, thereby leading to underestimation of coagulation factors levels, overestimation of antithrombin concentrations, false normalization of activated protein C resistance (APCR) and false positive lupus anticoagulant tests, depending on the reagents. [2] [3] [4] [5] [6] [7] [8] There is therefore a need to be able to neutralize dabigatran in vitro to carry out evaluation of pro-and anticoagulant factors in patients taking the drug.
Dabigatran can be neutralized in vivo by the administration of idarucizumab, a humanized antibody fragment. 9, 10 Idarucizumab has been successfully used in patients treated with dabigatran who developed live-threatening bleedings or who needed an urgent surgical intervention. 11, 12 We have recently demonstrated that the addition of idarucizumab to plasma samples prevented any interference of dabigatran in coagulations assays, thereby allowing to carry out detailed hemostasis and thrombophilia screenings for patients taking the drug. 13 Adsorbent tablets have recently been developed that can bind in vitro all types of direct oral anticoagulants present in test plasmas, with minimal effect on blood clotting tests compared to control plasmas without these anticoagulant. This may represent a convenient alternative to the addition of idarucizumab to neutralize dabigatran in plasma samples. We therefore compared the usefulness of adsorption and that of the addition of idarucizumab to normalize coagulation assays carried out with samples containing therapeutic and supratherapeutic levels of dabigatran. All assays were performed on an ACL-TOP 500 (Werfen, Brussels, Belgium), with the manufacturer's standard protocol as previously described. 13 The following reagents were used HemosIL SynthASil, 
| ME THODS

| RE SULTS
In a first series of experiments, we compared the amounts of dabigatran spiked into 1 mL of normal plasma that could be neutralized either by one tablet of adsorbent or by a given concentration of idarucizumab. A single final concentration of 625 μg/mL of idarucizumab was selected for these experiments as we had previously shown that in the absence of dabigatran such a concentration of idarucizumab did not interfere with any of the routine coagulation tests. 13 In agreement with our previous experiments, dabigran levels remained below the detection limit of our assay (3.4 ng/mL) F I G U R E 1 Neutralization of dabigatran by idarucizumab and by adsorbent material. A, A pool of plasma was supplemented with increasing concentrations of dabigatran. A fraction of the pool was then supplemented with idarucizumab at a final concentration of 625 μg/mL. Alternatively, samples supplemented with dabigatran were incubated for 5 min with one tablet of adsorbent material and centrifuged. The residual dabigatran concentrations were then measured in a diluted thrombin time test calibrated with dabigatran. The upper limit of the assay was 350 ng/mL. Tests with samples containing higher dabigatran concentrations were marked as failed. B, All samples were also analysed with a thrombin time test. Samples with a coagulation time >100 s were identified as failed (B). Results are expressed as means of 3 replicates. The coefficients of variation in the dilute thrombin time test calibrated with dabigatran and of the thrombin time test were ≤10% when up to 5000 ng/mL dabigatran was mixed with 625 μg/mL idarucizumab. 13 With higher concentration of dabigatran, the residual concentration of the drug raised above 350 μg/mL, the upper limit of the assay, despite the addition of idarucizumab ( Figure 1A ). After incubation with one adsorbent tablet, the residual concentration of dabigatran remained lower than the LOD of the assay when up to 10 000 ng/mL was added to the samples ( Figure 1A) . Furthermore, after incubation of one absorbent tablet with 20 000 ng/mL dabigatran, the concentration of the drug in the supernatant remained very low, at about 6 ng/mL ( Figure 1A) .
Similarly, when a thrombin time test was carried out with plasma spiked with 625 μg/mL idarucizumab and increasing concentrations of dabigatran, a normal coagulation time was observed up to 5000 ng/mL dabigatran ( Figure 1B ). In the presence of 10 000 ng/mL dabigratran or higher, the thrombin time prolonged to unmeasurable, in agreement with the observation that in such experimental conditions, a significant concentration of dabigatran was still detectable ( Figure 1A ). After incubation of dabigatran spiked plasma with adsorbent, the thrombin time was also normal up to 5000 ng/mL dabigatran. With concentrations of dabigatran ranging from 10 000 to 20 000 ng/mL, the thrombin time was prolonged but remained measurable ( Figure 1B ). The latter observation was in agreement with the low dabigatran concentrations (5-10 ng/mL) present in the supernatant after incubation of plasma containing 10 000 to 20 000 ng/mL dabigatran with adsorbent ( Figure 1A ). analysed. Similarly, the APCR assays carried out with pooled plasma spiked with dabigatran were normalized both by idarucizumab and by adsorption ( Figure 4D ). Because the adsorbent material may bind other molecules than dabigatran, we also determined whether F I G U R E 2 Neutralization of dabigatran by idarucizumab and by adsorbent in APTT, PT and fibrinogen assays. A pool of plasma was spiked or not with 5000 ng/mL dabigatran and supplemented with idarucizumab at a final concentration of 625 μg/mL or treated with adsorbent, before carrying out the APTT (A), PT (B) and fibrinogen (C) assays. Results are expressed as means of triplicates. The coefficient of variation in the APTT, PT, and fibrinogen tests were ≤2%, 3%, and 6% respectively patients' samples positive for the lupus anticoagulant tests and devoid of dabigatran would remain positive after adsorption. As shown in Figure 5 , the treatment of the samples from 3 patients with the adsorbent material did not reduce the positivity of any of the samples.
| D ISCUSS I ON
The addition of idarucizumab to plasma samples that contain dabigatran has been validated to neutralize the anticoagulant in vitro, thereby allowing to carry out routine coagulation assays in plasma from patients treated with the drug. To further evaluate the possibility of conveniently neutralizing dabigatran for coagulation assays, we compared the ability of the addition of idarucizumab and of adsorption of dabigatran to neutralize the activity of the drug in plasma samples.
Our objective was to validate methods that would be suitable for the routine hemostasis laboratory, even in cases of overdosage with the drug. In such circumstances, plasma concentrations of dabigatran up to 5600 ng/mL have been reported. 11, 14 In previous experiments, we have shown that the addition of 625 mg/mL to plasma was sufficient to fully neutralize up to 8000 ng/mL dabigatran. 13 This concentration of the antibody was therefore selected to compare the usefulness of idarucizumab to that of the adsorption of dabigatran to normalize coagulation assays.
In this study, we confirmed that the addition of 625 mg/mL idarucizumab was able to neutralize the activity of up to 5000 ng/mL dabigatran. Similarly, the treatment of plasma samples containing 10 000 ng/mL dabigatran with appropriate adsorbent fully removed dabigatran from plasma. In conclusion, our data demonstrated that the adsorption of dabigatran from plasma is as efficient as the addition of idarucizumab, thereby allowing to carry out routine coagulation assays in plasma samples from patients treated with this 
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